Sonova sees FY26 growth at low end of guidance, to sell Sennheiser consumer unit

Sonova flagged fiscal 2025-26 sales growth and normalized EBITA growth at the lower end of prior guidance (sales 5%-9% and EBITA 14%-18% at constant FX) after reporting FY24-25 sales of CHF 3.9bn and net profit of CHF 547m. The company announced plans to divest its Sennheiser consumer audio business (to be reclassified as discontinued operations) and reiterated strategic ambitions with a CHF 6.0bn revenue target for fiscal 2030-31 and medium-term sales CAGR of 5%-10% and core EBIT CAGR of 7%-12%.

Analysis

The guidance slip plus a carve-out of the Sennheiser consumer unit creates a two-stage market dynamic: near-term headline risk (earnings disappointment, sale execution uncertainty) followed by a multi-year capital allocation/strategy test as management pivots to a retail-led, lifestyle-hearing growth vector. Expect a 6–24 month disentanglement where headline volatility will dominate multiples even if the long-term CAGR target is achievable; that makes the stock sensitive to sale process milestones and any sign that proceeds will be redeployed into buybacks or low-return capex.

A less obvious consequence is margin mix shifting from OEM consumer audio to aftercare/recurring services — higher gross margin per user but greater need for working-capital and platform investment. This favors component and services suppliers that scale with connected premium devices (audio codec/MEMS vendors) and hurts independent audiology franchises that cannot match integrated retail analytics and product development sync. Private equity is the most likely buyer of Sennheiser’s consumer arm, which would compress supplier bargaining leverage short-term but could re-inflate ASPs for branded consumer headsets if a strategic buyer re-invests in marketing.

Key catalysts and tail risks are clear: buyer announcement or a disciplined capital return plan could re-rate the equity within 1–3 months; a protracted auction, a steep discount sale, or missed execution on retail integration could shave 20–35% off consensus earnings over 12 months. Regulatory/antitrust issues are low probability but a failed carve-out (operational separation problems) would push the timeline into years and materially increase execution risk.

Given the stretched multi-year revenue target, the appropriate investment horizon is bifurcated: trade the process over months and re-evaluate long-term positioning only after disposal terms and capital allocation are clear. Volatility will be the primary friend for arbitrageers and the enemy for directional holders until one or two clear post-sale uses of proceeds are announced.

Key Decisions for Investors

• Short SONOVA (SOON.SW) 3–6 month position / or buy 6-month at-the-money puts on any pop — thesis: near-term multiple compression as market reprices execution risk. Target -20% from current levels, stop if stock recovers +15% on credible buyback/clear sale terms. Expected payoff window 3–6 months.
• Event-driven long SONOVA exposure post-sale: buy Jan 2027 calls or accumulate stock only after buyer announced and management commits >50% of proceeds to buybacks/dividends — asymmetric 12–24 month R/R ~3:1 if capital returned and retail rollout scales as guided.
• Long Knowles (KN) 6–12 months — takt: suppliers of MEMS/codecs should see order catch-up if Sonova pushes premium lifestyle devices. Size 3–5% position, target +25% on visible order flow; hard stop -12% if Sonova guides no incremental sourcing.
• Pairs/arbitrage: Long selected independent audiology retail roll-ups or aftercare-service providers vs short public pure-play consumer-audio OEMs (e.g., a small-cap audio OEM) for 6–12 months — capture structural shift to services and monetization of lifetime customer value while hedging sector/systematic risk.